IP Library Granted Patent US 6,861,058
Granted Patent B2
US 6,861,058 · App. 09/883,122 · Granted Mar 1, 2005

Method for treating essential tremor with botulinum toxin type B

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,861,058
App. No.
09/883,122
Granted
Mar 1, 2005
Kind
B2
Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Claims (10)

1. A method for treating essential tremor, the method comprising the step of administering to a human patient an effective amount of a botulinum toxin type B formulation comprising sodium chloride- in order to treat essential tremor.

2. The method of claim 1 , wherein the botulinum toxin type B is administered by local administration.

3. The method of claim 2 , wherein the botulinum toxin type B is administered by intramuscular injection.

4. The method of claim 2 , wherein the botulinum toxin type B is administered by subcutaneous injection.

5. The method of claim 1 , wherein the administration of the botulinum toxin type B results in alleviation of a head or hand muscle tremor.

6. The method of claim 1 , wherein the patient is administered at least about 1,000 units of the botulinum toxin type B.

7. A method for treating essential tremor, the method comprising the step of local administration to a human patient of at least 1000 units of a botulinum toxin type B formulation comprising sodium chloride, the administration of the botulinum toxin type B formulation comprising sodium chloride resulting in an alleviation of a symptom of essential tremor.

8. The method of claim 7 , wherein the administration of the botulinum toxin type B results in alleviation of a head or hand muscle tremor.

9. A method for treating essential tremor the method comprising the step of intramuscular or subcutaneous administration to a human patient of at least 1000 units of a botulinum toxin type B formulation comprising sodium chloride, the administration of the botulinum toxin type B formulation comprising sodium chloride resulting in an alleviation of a symptom of essential tremor.

10. The method of claim 9 , wherein the administration of the botulinum toxin type B results in alleviation of a head or hand muscle tremor.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2014
From: JPMORGAN CHASE BANK, N.A.
To: SOLSTICE NEUROSCIENCES, LLC
Reel/Frame 033987/0440 →
SECURITY AGREEMENT Recorded Sep 26, 2012
From: SOLSTICE NEUROSCIENCES, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 029041/0720 →
MERGER Recorded Sep 6, 2012
From: SOLSTICE NEUROSCIENCES, INC.
To: SOLSTICE NEUROSCIENCES, LLC
Reel/Frame 028917/0475 →
RELEASE AND REASSIGNMENT Recorded Aug 10, 2010
From: NEXBANK, SSB
To: SOLSTICE NEUROSCIENCES, INC.
Reel/Frame 024812/0653 →
SECURITY AGREEMENT Recorded Mar 6, 2007
From: SOLSTICE NEUROSCIENCES, INC.
To: NEXBANK, SSB
Reel/Frame 018969/0513 →
Continuity (4)
Division 0949075600 · Jan 24, 2000
Division 0862711800 · Apr 3, 1996
Continuation 0817399600 · Dec 28, 1993
Related Publication 20010041181A1 · Nov 15, 2001